-+ 0.00%
-+ 0.00%
-+ 0.00%

On December 7, GlaxoSmithKline announced that its new targeted biologics can be used to treat systemic corticosteroids and/or the indications for adult patients with chronic sinusitis with nasal polyps that cannot be adequately controlled by surgery were included in the newly released “2025 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. Xinkelai is currently the only biological agent in China that covers the three major indications of eosinophilic granulomatous polyangiitis, severe eosinophilic asthma, and chronic sinusitis with nasal polyps, and these three indications have all entered the national medical insurance list.

Zhitongcaijing·12/07/2025 11:09:02
Listen to the news
On December 7, GlaxoSmithKline announced that its new targeted biologics can be used to treat systemic corticosteroids and/or the indications for adult patients with chronic sinusitis with nasal polyps that cannot be adequately controlled by surgery were included in the newly released “2025 National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue”. Xinkelai is currently the only biological agent in China that covers the three major indications of eosinophilic granulomatous polyangiitis, severe eosinophilic asthma, and chronic sinusitis with nasal polyps, and these three indications have all entered the national medical insurance list.